A Narrative Review of Staphylococcus hominis Resistance Pattern: Multidrug- and Possible Extensively Drug-Resistance

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Herleeyana Meriyani, Dwi Arymbhi Sanjaya, Rr. Asih Juanita, Desak Ketut Ernawati
{"title":"A Narrative Review of Staphylococcus hominis Resistance Pattern: Multidrug- and Possible Extensively Drug-Resistance","authors":"Herleeyana Meriyani, Dwi Arymbhi Sanjaya, Rr. Asih Juanita, Desak Ketut Ernawati","doi":"10.22146/ijp.5429","DOIUrl":null,"url":null,"abstract":"Staphylococcus hominis is the third most frequent opportunistic pathogen in neonates and immunosuppressed patients that cause bacteremia, septicemia, endophthalmitis, and endocarditis. The emergence of methicillin resistant Staphylococcus hominis (MRSHo) has been reported and is a growing concern. This review was intended to determine the susceptibility of Staphylococcus hominis to antibiotic agents with pharmacokinetics/pharmacodynamic approach. In addition, this review was determined the phenotypic criteria and antibiotic choice of Staphylococcus hominis infection. Four databases i.e., PubMed, PlosOne, ScienceDirect and Google Scholar were employed in searching process. Antibiotic resistance was identified using the minimum inhibitory concentration (MIC) and the percentage of resistance. The breakpoint value was based on The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MIC and zone diameters Version 11.0. There were 876 articles identified, 35 duplications were removed. These gave a total of 841 articles were screened yet 820 articles were irrelevant. Eventually, 21 articles were reviewed in this report. This review found that Staphylococcus hominis is potentially had MDR activity and a possible XDR bacterium that resistant to some antibacterial agents. The susceptibility of antibiotic to bacteria is not identical, and the regional reported drug resistance varies commonly due to differences in environment and antibiotic use. The resistance profile of Staphylococcus hominis is a complex interaction that affected by multifactorial such as: pharmacokinetics/pharmacodynamics index, mutant prevention concentration (MPC), mutant selection window (MSW), and the capability to produce biofilm.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":"3 1","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.5429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Staphylococcus hominis is the third most frequent opportunistic pathogen in neonates and immunosuppressed patients that cause bacteremia, septicemia, endophthalmitis, and endocarditis. The emergence of methicillin resistant Staphylococcus hominis (MRSHo) has been reported and is a growing concern. This review was intended to determine the susceptibility of Staphylococcus hominis to antibiotic agents with pharmacokinetics/pharmacodynamic approach. In addition, this review was determined the phenotypic criteria and antibiotic choice of Staphylococcus hominis infection. Four databases i.e., PubMed, PlosOne, ScienceDirect and Google Scholar were employed in searching process. Antibiotic resistance was identified using the minimum inhibitory concentration (MIC) and the percentage of resistance. The breakpoint value was based on The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MIC and zone diameters Version 11.0. There were 876 articles identified, 35 duplications were removed. These gave a total of 841 articles were screened yet 820 articles were irrelevant. Eventually, 21 articles were reviewed in this report. This review found that Staphylococcus hominis is potentially had MDR activity and a possible XDR bacterium that resistant to some antibacterial agents. The susceptibility of antibiotic to bacteria is not identical, and the regional reported drug resistance varies commonly due to differences in environment and antibiotic use. The resistance profile of Staphylococcus hominis is a complex interaction that affected by multifactorial such as: pharmacokinetics/pharmacodynamics index, mutant prevention concentration (MPC), mutant selection window (MSW), and the capability to produce biofilm.
人型葡萄球菌耐药模式:多药耐药和可能的广泛耐药
人型葡萄球菌是新生儿和免疫抑制患者中第三常见的机会致病菌,可引起菌血症、败血症、眼内炎和心内膜炎。耐甲氧西林人型葡萄球菌(MRSHo)的出现已被报道并引起越来越多的关注。本综述旨在通过药代动力学/药效学方法确定人型葡萄球菌对抗生素药物的敏感性。此外,本综述还确定了人型葡萄球菌感染的表型标准和抗生素的选择。检索过程采用PubMed、PlosOne、ScienceDirect和Google Scholar 4个数据库。采用最小抑菌浓度(MIC)和耐药百分比确定抗生素耐药性。断点值基于欧洲抗微生物药敏试验委员会(EUCAST)解释MIC和区直径的断点表。共发现876篇文献,删除35篇重复文献。总共有841篇文章被筛选,其中820篇文章是不相关的。最终,本报告审查了21篇文章。本综述发现人型葡萄球菌具有潜在的耐多药活性,也可能是一种对某些抗菌剂具有耐药性的XDR细菌。抗生素对细菌的敏感性并不相同,由于环境和抗生素使用的差异,各地区报告的耐药性普遍存在差异。人型葡萄球菌的耐药谱是一个复杂的相互作用过程,受药代动力学/药效学指数、突变体预防浓度(MPC)、突变体选择窗口(MSW)和产生生物膜的能力等多因素影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
INDONESIAN JOURNAL OF PHARMACY
INDONESIAN JOURNAL OF PHARMACY PHARMACOLOGY & PHARMACY-
CiteScore
1.20
自引率
0.00%
发文量
38
审稿时长
12 weeks
期刊介绍: The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信